Predictors of appropriate therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death

Heart International

Volumn 5, Issue 1, 2010, Pages 16-19

  Ahmed, Imdad ^a,b   Nelson, William B ^a,b   House, Chad M ^a   Zhu, Dennis W X ^a,b  

^a REGIONS HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Chronic kidney disease; ICD therapy; Metabolic syndrome; Systolic heart failure

Indexed keywords

AGED; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DEFIBRILLATOR; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIMARY PREVENTION; RETROSPECTIVE STUDY; RISK FACTOR; SUDDEN DEATH; SYSTOLIC HEART FAILURE;

EID: 77953473431     PISSN: 18261868     EISSN: 20362579     Source Type: Journal    
DOI: 10.4081/hi.2010.e4     Document Type: Article

References (28)

1. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
3. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachy - cardia Trial Investigators. N Engl J Med 1999;341:1882-90.
4. Hohnloser SH, Kuck KH, Dorian P, et al. DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8.
5. Winkle RA, Mead RH, Ruder MA, et al. Long term outcomes with the automatic implantable cardioverter efibrillator. J Am Coll Cardiol 1989;13:1353-61.
6. Bremner SM, McCauley KM, Axtell KA. A follow-up study of patients with implantable cardioverter efibrillators. Cardiovasc Nurs 1993;7:40-51.
7. Tebbenjohanns J, Schumacher B, Jung W, et al. Predictors of outcome in patients with implantable transvenous cardioverter defibrillators. Am Heart J 1994;127:1086-9.
8. Gradaus R, Block M, Brachmann J, et al. Mortality, morbidity, and complications in 3344 patients with ICDS: Results from the German ICD Registry EURID. Pacing Clin Electrophysiol 2003;26:1511-8.
9. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators. JAMA 2006;295: 165-71.
10. Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults treatment panel III). JAMA 2001;285:2486-92.
11. Iwao S, Iwao N, Muller DC et al. Does waist circumference add to the predictive power of the body mass. Obes Res 2001;9:685-95.
12. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without Creactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Pre vention Study. Circulation 2003;108: 414-9.
13. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
14. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
15. Hassan AA, Deswal A, Bozkurt B, et al. The metabolic syndrome and mortality in an ethnically diverse heart failure population. J Card Fail 2008:14:590-5
16. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004;27:2444-9.
17. Coelho FA, Moutinho MA, de Miranda VA, et al. The association between metabolic syndrome and its components and heart failure in patients referred to a primary care facility. Arq Bras Cardiol 2007;89:42-51.
18. Isomaa B, Almgren P, Tuomi T, et al. Cardio vascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
19. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA 2002;288:2709-16.
20. Levantesi G, Macchia A, Marfisi R, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005;46:277-83.
21. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004;110:1245-50.
22. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006;119:812-9.
23. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systemic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007;49: 403-14.
24. Segura J, Campo C, Gil P, et al. Develop-ment of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004;15: 1616-22.
25. Hreybe H, Ezzeddine R, Bedi M, et al. Renal insufficiency predicts the time to first appropriate defibrillator shock. Am Heart J 2006;151:852-6.
26. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-95.
27. Saxon LA, Bristow MR, Boehmer J, et al. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and De-fibrillation in Heart Failure (COMPANION) Trial. Circulation 2006;114:2766-72.
28. Buxton AE, Sweeney MO, Wathen MS, et al. QRS duration does not predict occurrence of ventricular tachyarrhythmias in patients with implanted cardioverterdefibrillators. J Am Coll Cardiol 2005;46:310-6.